The Infectious Disease Diagnostics Market, estimated at USD 1,750.8 Mn in 2025, is expected to exhibit a CAGR of 9.81% and reach USD 3,370.8 Mn by 2032.
The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.
Initiatives to address diagnostic challenges in emerging economies is expected to propel growth of the global infectious disease diagnostics market over the forecast period. For instance, In Aug 2025, Australian researchers at the Kirby Institute at UNSW Sydney, Burnet Institute, and Doherty Institute, along with international organizations, the Clinton Health Access Initiative and Foundation for Innovative New Diagnostics, have received US $5.2 million to improve laboratory capacity for testing and diagnosis of COVID-19, HIV, malaria, and tuberculosis in the Indo-Pacific region
Global Infectious Disease Diagnostics Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic had a positive impact on the Infectious Disease Diagnostics Market, due to huge expand growth in market of infectious disease diagnosis. In May 2025, Neuberg Diagnostic, a leading company that offers best-in-class laboratories, launched the clinical laboratory's operation in the U.S. to offer genomic and molecular testing on new generation sequencing technology.
Global Infectious Disease Diagnostics Market: Key Developments
On December 15th, 2025; Roche announced the launch of the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardised performance and efficiencies across low, medium and high volume molecular laboratory testing needs.
On October 11th, 2025; Aegis Sciences Corporation expanded its molecular testing capabilities to rapidly identify pathogens in the respiratory and urogenital health spaces. With Aegis Infectious Disease Testing, providers will have access to: Clinically relevant tests for a wide variety of pathogens and condition, diversity in specimen collection options, 24-hour turnaround time, semi-quantitative reporting available where clinically appropriate and clear, reliable, and actionable results. The testing menu includes customizable order options for the most common pathogens that cause respiratory tract infections (RTIs), genital health/sexually transmitted infections (STIs), gastrointestinal infections (GIs) and urinary tract infections (UTIs).
The factors driving the growth of Europe's infectious disease diagnostics market are government funds to cure the infectious diseases and rising cases of infectious diseases. According to the, European Institute of Innovation & Technology (EIT) Health had declared funds of almost $7.69 million (7 million euros) in the fight against Covid-19, which be dedicated to 15 health innovation projects across Europe. The project focuses on direct and impactful solutions for better tools in navigating the pandemic.
In March 2025, Chembio Diagnostics, Inc., a point-of-care Diagnostics Company focused on infectious diseases, completed the technical feasibility phase for a potential companion/compatible diagnostic test being developed in collaboration with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
On March 27th, 2025, Abbott announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.
Browse 28 Market Data Tables and 22 Figures spread through 120 Pages and in-depth TOC on “Global Infectious Disease Diagnostics Market By Technique ( ELISA, Polymerase Chain Reaction (PCR),Immunoassays, Cell Cultures, Others),By Disease Indication (CNS Infection ,Meningitis, Brain Abscess), Diarrheal Disease (Shigellosis, Cholera, Enteric/Typhoid Fever),Respiratory Infections(Tuberculosis,Influenza,Bronchitis),Blood Infections(Malaria, Dengue, Infectious Mononucleosis,Others),STDs(Chlamydia,Aids,Syphills,Others)),By End User (Hospitals,Diagnostic Centers,Clinics,Government Organizations), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/infectious-disease-diagnostics-market-1971
Key Takeaways of the Global Infectious Disease Diagnostics Market:
- The cell cultures segment is expected to dominate the market during the forecast period. Several types of infections can be diagnosed using cell culture, as microbes can be grown in a laboratory setting
- The STDs segment held dominant position in the global infectious disease diagnostics market followed by Central Nervous System infection, and respiratory infections, respectively. Increasing sexually transmitted disease burden is fueling growth of the segment. Among 20 STDs, the most common are Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus (HIV).For Instance,In June 2025, WHO , WHO estimated 374 million new infections with 1 of 4 STIs: chlamydia (129 million), gonorrhoea (82 million), syphilis (7.1 million) and trichomoniasis (156 million).
In End Users, Clinics segment in the global infectious disease .In 2025, diagnostics market is accounted for share during the forecast period. Central diagnostic laboratories are well equipped with latest diagnostic instruments and have large resources to carry out multiple tests. Large number of tests are carried out on a daily basis in these centers which supports growth of the hospital segment and healthcare infrastructure for treatment.
Contact Us